期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.675870
关键词
gastric cancer; liver metastasis; hepatectomy; interventional therapy; network analysis
类别
资金
- National Natural Science Foundation of China [81902498]
- Hubei Provincial Natural Science Foundation [2019CFB450, 2019CFB177, 2016CFB530]
- Natural Science Foundation of Hubei Provincial Department of Education [Q20182105]
- Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Provincial [CXPJJH11800001-2018333]
- The Scientific and Technological Project of Shiyan City of Hubei Province [18Y35]
- The Foundation of Health and Family Planning Commission of Hubei Province [WJ2021Q007]
- Innovation and Entrepreneurship Training Program [201810929005, 201810929009, 201810929068, 201813249010, S201910929009, S201910929045, S202013249005, S202013249008, 202010929009]
This study evaluated the effects of surgical treatments-based chemotherapy in the treatment of gastric cancer with liver metastases (GCLM). Results showed that HGCT and RFAG were more effective than other treatment options, with RFAG identified as the best option for overall survival and HGCT for 1-year survival rate. The study concluded that HGCT and RFAG have significant survival benefits for GCLM patients.
BackgroundThis study aimed at evaluating the effects of surgical treatments-based chemotherapy in the treatment of gastric cancer with liver metastases (GCLM). It has not been established whether Liver-directed treatment (LDT) options such as hepatectomy and gastrectomy plus chemotherapy (HGCT), radiofrequency ablation and gastrectomy plus chemotherapy (RFAG), transarterial chemoembolization and gastrectomy plus chemotherapy (TACEG), gastrectomy plus chemotherapy (GCT) enhance the survival of GCLM patients. MethodsWe performed systematic literature searches in PubMed, EMBASE, and Cochrane library from inception to September 2021. We created a network plot to comprehensively analyze the direct and indirect evidence, based on a frequentist method. A contribution plot was used to determine inconsistencies, a forest plot was used to evaluate therapeutic effects, the publication bias was controlled by funnel plot, while the value of surface under the cumulative ranking curves (SUCRA) was calculated to estimate rank probability. ResultsA total of 23 retrospective studies were identified, involving 5472 GCLM patients. For OS and 1-, 2-, 3-year survival rate of all trials, meta-analysis of the direct comparisons showed significant better for HGCT treatments compared with GCT or PCT. In the comparison of the 5 treatments for 1-, 2-, 3-year survival rate, HGCT and RFAG were found to be more effective than GCT and PCT, respectively. By OS and 2-, 3-year survival rate analysis, RFAG was identified as the best option, followed by HGCT, TACEG, GCT and PCT. By 1-year survival rate analysis, HGCT and RFAG were identified as the most effective options. ConclusionHGCT and RFAG has remarkable survival benefits for GCLM patients when compared to TACEG, GCT and PCT. HGCT was found to exhibit superior therapeutic effects for GCLM patients for 1-year survival rate while RFAG was found to be a prospective therapeutic alternative for OS and 2-, 3-year survival rate. Systematic Review Registrationidentifier [10.37766/inplasy2020.12.0009].
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据